<DOC>
	<DOCNO>NCT01449292</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy AeriSeal System treatment plus optimal medical therapy compare patient advance upper lobe predominant ( ULP ) heterogeneous emphysema .</brief_summary>
	<brief_title>Study AeriSeal System HyPerInflation Reduction Emphysema ( ASPIRE )</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>1 . Willing able provide inform consent 2 . Age ≥ 40 year 3 . On optimal medical therapy* 1 month 4 . Advanced upper lobe predominant emphysema confirm CT scan 5 . Two ( 2 ) subsegments appropriate treatment 2 different upper lobe segment lung base upon CT scan ( total 4 available subsegments ) 6 . MRCD score ≥ 2 post pulmonary rehab ( use modify MRCD scale 04 ) 7 . 6MWT distance ≥ 150 post pulmonary rehab 8 . Spirometry 15 minute administration bronchodilator show BOTH : 1 . FEV1 &lt; 50 % predict 2 . FEV1/FVC ratio &lt; 70 % 9 . Plethysmographic lung volume show BOTH : 1 . TLC &gt; 100 % predict 2 . RV &gt; 150 % predict 10 . DLco ≥ 20 % ≤ 60 % predict 11 . Blood gas oxygen saturation show BOTH : 1 . SpO2 ≥ 90 % ≤ 4 L/min supplemental O2 2 . PaCO2 &lt; 65 torr 12 . Smoking history ≥ 20 packyears abstinence 16 week 1 . Prior lung volume reduction surgery , lobectomy pneumonectomy , lung transplantation 2 . Requirement ventilator support ( CPAP BPAP sleep apnea ) 3 . Three ( 3 ) COPD exacerbation require hospitalization within 1 year Screening visit COPD exacerbation require hospitalization within 8 week 4 . Use systemic steroid &gt; 20 mg/day equivalent immunosuppressive agent , heparin , oral anticoagulant investigational medication Exclusion Criteria ( continue ) : 5. a1 antitrypsin serum level &lt; 80 mg/dL ( immunodiffusion ) &lt; 11 µmol/L ( nephelometry ) 6 . CT scan : Presence follow radiologic abnormality : 1 . Pulmonary nodule CT scan great 1.0 cm diameter 2 . Radiologic picture consistent active pulmonary infection 3 . Significant interstitial lung disease 4 . Significant pleural disease 5 . Giant bullous disease 7 . Clinically significant asthma 8 . Clinically significant bronchiectasis 9 . Pulmonary hypertension 10 . Allergy sensitivity medication require safely perform AeriSeal System treatment general anesthesia conscious ( moderate procedural ) sedation 11 . Participation investigational study drug , biologic , device currently approve market 12 . Body mass index &lt; 15 kg/m2 &gt; 35 kg/m2 13 . Female patient pregnant breastfeed planning pregnant next year 14 . Any abnormal screening laboratory test result 15 . Significant comorbidity include follow : 1 . HIV/AIDs 2 . Active malignancy 3 . Stroke TIA within 12 month 4 . Myocardial infarction within 12 month 5 . Congestive heart failure within 12 month 16 . Any condition would interfere intent study would make participation best interest patient alcoholism , high risk drug abuse noncompliance return followup visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>PLVR</keyword>
	<keyword>ELVR</keyword>
	<keyword>AeriSeal System</keyword>
	<keyword>foam sealant</keyword>
	<keyword>emphysematous lung sealant</keyword>
	<keyword>ELS</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
	<keyword>polymeric lung volume reduction</keyword>
	<keyword>heterogeneous</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>